Efficacy of Sulfonylureas with Insulin in Type 2 Diabetes Mellitus

Annals of Pharmacotherapy

Volumn 37, Issue 11, 2003, Pages 1572-1576

  Kabadi, Mary U ^a   Kabadi, Udaya M ^a,b,c  

^a CARL T HAYDEN VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Glycemic control; Insulin; Sulfonylureas; Type 2 diabetes mellitus

Indexed keywords

C PEPTIDE; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLYCOSYLATED HEMOGLOBIN; INSULIN; ISOPHANE INSULIN; METFORMIN; PLACEBO; SULFONYLUREA DERIVATIVE; TOLAZAMIDE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FEMALE; GASTROINTESTINAL THERAPEUTIC SYSTEM; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS;

BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INSULIN; MALE; MIDDLE AGED; SULFONYLUREA COMPOUNDS;

EID: 0142182483     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1C492     Document Type: Article

References (39)

1. Riddle M, Hart JS, Bouma DJ, Phillipson BE, Youker G. Efficacy of bedtime NPH insulin in treatment of secondary failure to glibenclamide. Diabetes Care 1989;12:582-5.
2. Sontaniemi E. Insulin and sulfonylurea in the therapy of type 2 diabetes. Diabetes Res Clin Pract 1990;8:243-51.
3. Simpson H, Sturley R, Stirling C, Reckless J. Combination of insulin with glipizide increases peripheral glucose disposal in secondary failure type 2 diabetic subjects. Diabet Med 1990;7:143-7.
4. Del Prato S, Vigili de Kreutzenberg S, Riccio A, Maifreni L, Duner E, Lisato G, et al. Partial recovery of insulin secretion and action after combined insulin-sulfonylurea treatment in type 2 (non-insulin-dependent) diabetic subjects with secondary failure to oral agents. Diabetologia 1990;33:688-95.
5. Groop L, Widen E. Treatment strategies for secondary sulfonylurea failure. Diabete Metab 1991;17:218-23.
6. Kabadi U, Kabadi M. Type II diabetic subjects with secondary failure: treatment with pre-breakfast mixed ultralente and regular insulin with a sulfonylurea. J Fam Pract 1991;33:349-53.
7. Yki-Jarvinen H, Kauppila M, Kujansuue E, Lahti J, Marjanen T, Niskanen L, et al. Comparison of insulin regimens in subjects with non-insulin dependent diabetes mellitus. N Engl J Med 1992;329:1426-33.
8. Johnson JL, Wolf SL, Kabadi UM. Efficacy of insulin and sulfonylurea combination therapy in type 2 diabetes mellitus. Arch Intern Med 1996; 156:259-64.
9. Lindstrom T, Nystrom FH, Olsson AG, Arnqvist HJ. The lipoprotein differs during insulin treatment alone and combination therapy with insulin and sulfonylureas in subjects with type 2 diabetes mellitus. Diabet Med 1999;16:820-6.
10. Wright A, Felix Burden AC, Paisey RB, Cull CA, Holman RR. Sulfonylurea inadequacy. Diabetes Care 2002;25:330-6.
11. Muller G, Satoh Y, Geisen K. Extrapancreatic effects: a comparison between glimepiride and conventional sulfonylureas. Diab Res Clin Pract 1995;(suppl 28):115s-37s.
12. Muller G, Geisen K. Characterization of the molecular mode of action of the sulfonylurea, glimepiride at adipocytes. Horm Metab Res 1996;28: 469-87.
13. Draeger KE, Wernicke-Panten K, Lomp HJ, Schuler E, Rosskamp R. Long term treatment of type 2 diabetic subjects with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide. Horm Metab Res 1996;28:419-25.
14. Dills DG, Schneider J. Clinical evaluation of glimepiride vs. glibenclamide in NIDDM in a double blind comparative study. Horm Metab Res 1996;28:426-9.
15. Massi-Benedetti M, Herz M, Pfeiffer C. The effects of acute exercise on metabolic control in type II diabetic subjects treated with glimepiride or glibenclamide. Horm Metab Res 1996;28:451-5.
16. Riddle MC, Schneider J, The Glimepiride Combination Group. Beginning insulin treatment of obese subjects with evening 70/30 insulin plus glimepiride versus insulin alone. Diabetes Care 1998;21:1052-7.
17. American Diabetes Association. Position statement standards of medical care for subjects with diabetes mellitus. Diabetes Care 2002;25(suppl 1): S49-53.
18. Schwartz S, Raskin P, Fonesca V, Graveline J. Effect of troglitazone in insulin-treated subjects with type II diabetes mellitus. N Engl J Med 1998;338:861-6.
19. Buse JB, Gumbiner B, Mathias NP, Nelson DB, Faja BW, Whitcomb RW. Troglitazone use in insulin-treated type 2 diabetic subjects. Diabetes Care 1998;21:1455-61.
20. Yu JG, Kruszynska YT, Mulford MI, Olefsky JM. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic subjects. Diabetes 1999;48:2414-21.
21. Golay A, Guillet-Dauphine N, Fendel A, Juge C, Assal JP. The insulin-sparing effect of metformin in insulin-treated diabetic subjects. Diabetes Metab Rev 1995;11(suppl):S63-7.
22. Giugliano D, Quatraro A, Consoli G, Minei A, Ceriello A, De Rosa N, et al. Metformin for obese, insulin-treated diabetic subjects: improvement in glycemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol 1993;44:107-12.
23. Slama G. The insulin sparing effect of metformin in insulin-treated diabetic subjects. Diabetic Metab 1991;7:241-3.
24. Chaudhuri A, Tomar R, Moharty P, Szudzik E, Bandyopadhyay A, Arian M, et al. The combination of insulin and metformin in treatment of non-insulin dependent diabetes mellitus. Endocrine Pract 1998;4:259-67.
25. Feldman JM, Lebovitz HE. An insulin-dependent effect of chronic tolbutamide administration on the skeletal muscle carbohydrate transport system. Diabetes 1969;18:84-95.
26. Blumenthal SA. Potentiation of the hepatic action of insulin by chlorpropamide. Diabetes 1977;26:485-9.
27. Lebovitz HE, Feinglos MN. Sulfonylurea drugs: mechanism of anti-diabetic action and therapeutic usefulness. Diabetes Care 1978;1:189-98.
28. Beck-Nielsen H, Pederson O, Lindsdov HO. Increased insulin sensitivity and cellular insulin binding to obese diabetics following treatment with glibenclamide. Acta Endocrinol 1979;90:451-62.
29. Olefsky JM. Insulin resistance and insulin action: an in vitro and in vivo perspective. Diabetes 1981;20:148-62.
30. Bieger W, Dlugosch R, Rettenmeier A, Holler H, Ber H, Schwarz W, et al. Trial of sulfonylurea in combination with insulin in the therapy of diabetes type 1 and 2. Klin Wochenschr 1984;62:631-9.
31. Pontiroli AE, Albertto A, Beroletti G, Baio G, Pozza G. Sulfonylurea enhances in vivo the effectiveness of insulin in type 1 (insulin dependent) diabetes mellitus. Horm Metab Res 1984;16:167-70.
32. Pernet A, Trimble ER, Kunstchen F, Assal JPH, Hahn C, Reynold AE. Sulfonylurea in insulin-dependent (type 1) diabetes: evidence for an extrapancreatic effect in vivo. J Clin Endocrinol Metab 1985;61:247-51.
33. Garrel DR, Picq R, Bajard L, Harfouche M, Tourniare J. Acute effect of glibenclamide on insulin sensitivity in type 1 diabetic subjects. J Clin Endocrinol Metab 1987;65:896-900.
34. Kabadi UM. Adjuvant therapy with tolazamide and insulin improves metabolic control in type 1 diabetes mellitus. Diabetes Care 1985;8:440-6.
35. Kabadi UM, Birkenholz MR. Improved metabolic control in insulin-dependent diabetes mellitus with insulin and tolazamide. Arch Intern Med 1988;148:1745-9.
36. Kabadi UM, McCoy S, Birkenholz M, Kabadi M. More uniform diurnal blood glucose control and a reduction in daily insulin dosage on addition of glibenclamide to insulin in type 1 diabetes mellitus: role of enhanced insulin sensitivity. Diabet Med 1995;12:880-4.
37. Blak JF, Schmitz O, Sorensen NS, Pedersen O. Postreceptor effects of sulfonylurea on skeletal muscle glycogen synthase activity in type II diabetic subjects. Diabetes 1989;38:1343-50.
38. Rosskamp R, Wrnicke-Painten K, Draeger E. Clinical profile of the novel sulfonylurea glimepiride. Diab Res Clin Pract 1996;311(suppl):S33-42.
39. Clark HE, Matthews DR. The effect of glimepiride on pancreatic beta cell function under hyperglycemic clamp and hyperinsulinemia euglycemic clamp conditions in NIDDM. Horm Metab Res 1996;28:445-50.